TCWP’s Charles River Laboratories CRL Stock Holding History

TCWP’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-45	Closed	-$12K	–	612
2022 Q1	$12K	Buy	+45	New	+$13.9K	﹤0.01%	830

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCWP's CRL Position: Q2 2022 in Review

TCWP sold out of Charles River Laboratories (CRL) in Q2 2022, closing a stake of 45 shares — an estimated $12K sold.

TCWP first reported a position in CRL in Q1 2022 and held it in 1 quarter. The position peaked at $12K in Q1 2022. 627 funds tracked by Wall St. Rank hold CRL as of Q2 2022.

TCWP reported no remaining Charles River Laboratories position as of Q2 2022 after selling out during the quarter.
TCWP sold 45 Charles River Laboratories shares in Q2 2022, an estimated $12K.
TCWP first reported a position in Charles River Laboratories in Q1 2022 and held it in 1 quarter.
TCWP's Charles River Laboratories position peaked at $12K in Q1 2022.
627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.